Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**CAN-1** is an official Spanish registry identifier for one of the first standardized medicinal cannabis preparations registered by Curaleaf with the Spanish Agency of Medicines and Medical Devices. Curaleaf disclosed that CAN-1 and CAN-2 correspond to two distinct preparations, one THC-dominant and one CBD-dominant, but did not publicly assign the cannabinoid composition specifically to CAN-1. The preparation is intended for supply to hospital pharmacies for preparation of patient-specific magistral cannabis formulas under Spain's medicinal-cannabis framework. ([ir.curaleaf.com](https://ir.curaleaf.com/2026-07-13-Curaleaf-First-to-Secure-Registration-for-Standardized-Cannabis-Preparations-in-Spain))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CAN-1.